Impella® Quality Assurance Program: Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery
Data from Abiomed’s Impella® Quality (IQ) Assurance Program, which includes the IQ Database and cVAD Registry, was presented today as late-breaking Featured Clinical Research by Dr. William O'Neill of Henry Ford Hospital System at the American College of Cardiology (ACC) 66th Annual Scientific Session in Washington, D.C. These data were derived from the IQ Database documenting the real-world treatment of approximately 50,000 U.S. patients, with a subset of 15,259 Acute Myocardial Infarction Cardiogenic Shock (AMICS) patients. The Impella heart pump results indicate an association between the use of best practice protocols and improved survival and native heart recovery, as compared to inconsistent treatment or inexperienced hospitals.
Learn More:
- Explore information and coverage of the Detroit Cardiogenic Shock Initiative, a real-world application of standardized protocols.
- Download protocols and best practices to identify, stabilize, and asses cardiogenic shock patients.
- Read Abiomed's press release on the Impella Quality Assurance Program.
IMP-107-17
To learn more about the Impella® platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: abiomed.com/important-safety-information
